Compare DoorDash Inc (DASH) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Mesoblast Limited — how do they compare? DoorDash Inc trades at $211.99 (market cap $90.93B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: DoorDash Inc is far larger — about 42.1× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| DASH | MESO | |
|---|---|---|
Market Cap | $90.93B | $2.16B |
Sector | Consumer Cyclical | Technology |
52-Week High | $281.74 | $20.96 |
52-Week Low | $146.60 | $12.88 |
Enterprise Value | $88.89B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $216.26, up 1.41% with strong technical momentum above key support levels. The company demonstrates robust revenue growth, with Q2 2026 revenue up 36% YoY to $4.45B, though earnings missed estimates due to higher R&D costs. Analyst sentiment remains overwhelmingly positive with 75.68% buy ratings and a $247.41 consensus price target, representing 14.4% upside potential from current levels.
DoorDash's expansion into grocery, retail, and international markets supports growth, but elevated valuation multiples (P/E 113.23) and intense competition present risks. The stock's technical strength and fundamental growth trajectory suggest continued upside, though investors should monitor execution on profitability targets and competitive pressures in the delivery space.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
